Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Edicotinib (JNJ-527) is a brain penetrant and orally active inhibitor of the colony-stimulating factor-1 receptor (IC50: 3.2 nM). It shows less inhibitory effects on KIT and FLT3 (IC50: 20 nM and 190 nM). It has the potential for Alzheimer's disease and rheumatoid arthritis treatment.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 64.00 | |
2 mg | In stock | $ 93.00 | |
5 mg | In stock | $ 155.00 | |
10 mg | In stock | $ 228.00 | |
25 mg | In stock | $ 397.00 | |
50 mg | In stock | $ 583.00 | |
100 mg | In stock | $ 813.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 158.00 |
Description | Edicotinib (JNJ-527) is a brain penetrant and orally active inhibitor of the colony-stimulating factor-1 receptor (IC50: 3.2 nM). It shows less inhibitory effects on KIT and FLT3 (IC50: 20 nM and 190 nM). It has the potential for Alzheimer's disease and rheumatoid arthritis treatment. |
Targets&IC50 | FLT3:190 nM, c-Kit:20 nM , CSF1R:3.2 nM |
In vitro | Edicotinib (0.1 nM-1μM; 24 hours) causes a dose-dependent decrease of CSF1R activation. Edicotinib (0.1 nM-1μM; 24 hours) lead to a concurrent reduction of ERK1 and ERK2 phosphorylation. The dose-response curve displays the effect of Edicotinib on CSF1R and ERK1/2 (IC50: 18.6 nM and 22.5 nM for CSF1R and ERK1/2) [1]. |
In vivo | Edicotinib (oral gavage; 30 mg/kg; 33 days) significantly reduces the density of microglia in CA1 of the hippocampus of ME7-prion mice (PU.1+ cells) by up to 30%. And the expression of IL-1β is also reduced, however not other inflammatory cytokines. Edicotinib (oral gavage; 3, 10, 30, and 100 mg/kg; 5 days) obviously inhibits microglial proliferation in ME7 mice.?It reduces the number of microglia (total CD45+CD11b+ cells) only at the highest dose tested of 100 mg/kg. At every dose tested (CD45+CD11b high Ly6C intermediate/low cells), JNJ-527 depletes up to 50% of patrolling blood monocytes. Only a tendency for a reduction in the proportion of inflammatory monocytes (Ly6C high?cells) at 100 mg/kg [1]. Edicotinib displays a good pharmacokinetic/pharmacodynamics (PK/PD) profile, the microglial proliferation data shows an EC50 of 196/ml and 69 ng/g calculated from plasmatic and brain compound concentration, respectively [1]. |
Synonyms | JNJ-527, JNJ-40346527 |
Molecular Weight | 461.6 |
Formula | C27H35N5O2 |
CAS No. | 1142363-52-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15 mg/mL (32.4 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Edicotinib 1142363-52-7 Angiogenesis Tyrosine Kinase/Adaptors c-Kit CSF-1R FLT c-Fms colony stimulating factor 1 receptor CSF-1 receptor JNJ40346527 inhibit neurodegeneration CSF1R JNJ-527 JNJ527 Inhibitor expansion alzheimer’s disease JNJ 527 rheumatoid microglial JNJ-40346527 JNJ 40346527 arthritis inhibitor